The Researcher's Guide to Peptides: Which Compound Is Right for Your Study?

Choosing the right peptide for a research protocol isn't a product decision — it's a mechanistic one. The compound you select determines what questions you can ask, what variables you can control, and what your data will actually mean.

This guide maps the most commonly researched peptide compounds to their primary mechanisms and research applications, so you can match the tool to the question.

How to Use This Guide

Start with your research endpoint, not the compound. Ask: what biological process am I trying to study or modulate? Then identify which receptor or pathway is most relevant to that process. The compound selection follows from there.

Metabolic and Endocrine Research

GLP-1 Class: Semaglutide, Tirzepatide, Retatrutide

These three compounds share GLP-1 receptor agonism as a common mechanism but differ significantly in their additional receptor targets — and those differences determine which research questions each one can answer.

For a detailed mechanism-by-mechanism comparison, see our 2024–2025 GLP-1 class comparison.

MOTS-c

MOTS-c is a mitochondria-derived peptide — encoded by mitochondrial DNA rather than nuclear DNA — that activates AMPK and regulates cellular energy homeostasis. It is the appropriate tool when the research question involves mitochondrial signaling, exercise biology, or metabolic aging.

Best for: AMPK pathway research, exercise mimetic studies, metabolic aging models, insulin resistance with a mitochondrial component, longevity pathway investigation.

See the full MOTS-c research guide.

Tissue Repair Research

BPC-157

BPC-157 is the most extensively studied peptide in preclinical tissue repair research. Its primary mechanisms — VEGF upregulation, nitric oxide system modulation, and FAK-paxillin pathway activation — make it the standard tool for local tissue repair models.

Best for: Tendon and ligament repair, muscle healing, GI cytoprotection, wound healing, vascular research, neurological models.

See the full BPC-157 research guide.

TB-500 (Thymosin Beta-4)

TB-500 acts systemically rather than locally — its primary mechanism involves actin polymerization regulation and cell migration promotion. It is the appropriate tool when the research question requires systemic anti-inflammatory effects or cell migration as a variable.

Best for: Systemic tissue repair, cardiac regeneration models, muscle regeneration, anti-inflammatory research, cell migration studies.

GHK-Cu (Copper Peptide)

GHK-Cu targets extracellular matrix remodeling through collagen synthesis upregulation and MMP modulation. It is the appropriate tool when the research question involves the ECM component of tissue repair rather than the vascular or inflammatory components.

Best for: Collagen synthesis research, skin biology, wound healing with ECM focus, hair follicle research, neuroprotection models.

Combination Protocols

BPC-157 + TB-500 (Wolverine Stack) targets tissue repair through complementary local and systemic pathways. GHK-Cu + TB-500 + BPC-157 (GLOW blend) adds ECM remodeling to the combination. See the GLOW blend research guide for mechanistic rationale.

Decision Framework

Quality Standards for Research Use

Regardless of which compound you select, the quality requirements are the same: ≥99% HPLC-verified purity, endotoxin screening (<0.1 EU/mg), lot-specific Certificate of Analysis, and ISO-certified manufacturing. These aren't optional — they're the baseline for producing interpretable data.

For guidance on verifying supplier quality claims, see our peptide purity verification guide.

Star Valley Peptides carries all compounds listed in this guide. Full catalog at peptidespro.online. For bulk orders or protocol consultation: 94300791@qq.com

References

1. Lee, C., Zeng, J., Drew, B.G., et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 21(3), 443–454. PubMed: 25738459
2. Wilding, J.P.H., Batterham, R.L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 384, 989–1002. PubMed: 33567185
3. Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 387, 205–216. PubMed: 35658024
4. Jastreboff, A.M., Kaplan, L.M., Frías, J.P., et al. (2023). Triple–hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. New England Journal of Medicine, 389, 514–526. PubMed: 37366315
5. Sikiric, P., Seiwerth, S., Rucman, R., et al. (2013). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 17(16), 1612–1632. PubMed: 21548867
6. Goldstein, A.L., Hannappel, E., Sosne, G., & Kleinman, H.K. (2012). Thymosin β4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy, 12(1), 37–51. PubMed: 22107104

All products sold by Star Valley Peptides are strictly for laboratory and scientific research purposes only. Not intended for human or animal therapeutic use. Not approved by any regulatory authority for clinical application.